drugset / Trial / NCT06246786

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

NCT06246786

Phase 0 Withdrawn Virginia G. Kaklamani
NaSingle-groupOpen-labelTreatment

Summary

This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.

Timeline

Start
2024-07-01
Primary completion
2025-06-23
Completion
2025-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 5 mg/kg